NFKB1 and rhabdomyolysis: [91] found that recombinant human erythropoietin (rhEPO) could inhibit the activity of NF-κB and iNOS, reduce the expression of BUN, Cre, GOT, GPT, and CPK which are kidney injury markers after rhabdomyolysis, and relieve AKI induced by rhabdomyolysis in rats.